SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-16-566264
Filing Date
2016-04-29
Accepted
2016-04-29 08:20:37
Documents
7
Effectiveness Date
2016-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A d98255ddefa14a.htm DEFA14A 35227
2 GRAPHIC g98255g05e15.jpg GRAPHIC 23408
3 GRAPHIC g98255g16q56.jpg GRAPHIC 13701
4 GRAPHIC g98255g50i50.jpg GRAPHIC 16914
5 GRAPHIC g98255g62d05.jpg GRAPHIC 24728
6 GRAPHIC g98255g76c99.jpg GRAPHIC 32714
7 GRAPHIC g98255g87n84.jpg GRAPHIC 13084
  Complete submission text file 0001193125-16-566264.txt   208382
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36296 | Film No.: 161602622
SIC: 2834 Pharmaceutical Preparations